This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Carcinoid syndrome

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Carcinoid tumours describe a range of neoplasms arising from neuroendocrine cells or their precursors. Of intestinal carcinoids, the most common sites are in the midgut, especially the appendix and terminal ileum. Non-intestinal carcinoids include those of the lung, testes and ovary. They are usually of low-grade malignancy.

The carcinoid syndrome develops when products, chiefly serotonin, are released by the tumour in large amounts and escape hepatic degradation (1,2)

  • caused by the release of serotonin and other substances from well-differentiated neuroendocrine tumours (NETs)
  • hallmark symptoms of carcinoid syndrome are:
    • flushing and diarrhea
    • atypical signs and symptoms can include:
      • wheezing,
      • abdominal pain,
      • valvular heart disease,
      • telangiectasias, pellagra,
      • complications of mesenteric fibrosis, including ureteral obstruction, bowel obstruction, and bowel ischemia

  • symptoms are mediated by the release of serotonin (5-HT), histamine, kallikrein, prostaglandins, and tachykinins

Carcinoid syndrome:

  • is a paraneoplastic syndrome associated with the secretion of approximately 40 vasoactive hormones, predominantly 5-hydroxytryptamine (5-HT) (1)
    • also involves the secretion of histamine (primary gastric NETs), kallikrein, prostaglandins E and F, and tachykinins
    • NETs can arise in the foregut, midgut, or hindgut

The carcinoid syndrome is seen in two situations:

  • intestinal carcinoids with hepatic metastases:
    • the metastases reach sizes several times larger than that of the primary tumour and secrete products into the hepatic vein
    • the vasoactive tumour products are able to enter the systemic circulation
  • extra-intestinal carcinoids

Epidemiological studies from the US suggest the age-adjusted incidence of carcinoid tumours varies between 2.47 and 4.48 per 100,000 population, with the rates being highest in black males, then black females, then white Americans (1)

  • population corrected male-to-female ratio for all carcinoid sites was 0.86
  • average age at diagnosis for all carcinoid tumours was 61.4 years (compared with 63.9 years for non-carcinoid tumours)

Diagnosis

  • requires these symptoms and corresponding elevations in lab tests

Treatment options include surgery and medical management with somatostatin analogs

Reference:

  1. Endocr Relat Cancer. 2004 Mar;11(1):1-18.
  2. Gade AK, Olariu E, Douthit NT. Carcinoid Syndrome: A Review. Cureus. 2020 Mar 5;12(3):e7186. doi: 10.7759/cureus.7186.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.